Aesthetic surgery journal · 2025
The Wonder of Sutureless Müllerectomy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Atar-Vardi Maya, Dubinsky-Pertzov Biana, Butnik-Cohen Shir, Hartstein Morris E, Stein Ran
Аннотация
BACKGROUND: Müller muscle-conjunctival resection (MMCR) is a possible treatment for some cases of ptosis. Corneal irritation or erosions are potential complications due to the use of sutures.
OBJECTIVES: The aim of this study was to evaluate the efficacy and safety of sutureless MMCR as a treatment for moderate to severe ptosis, and to assess postoperative eyelid symmetry and surgical success rates.
METHODS: A retrospective, single-center cohort study was performed. Patients with a positive response to phenylephrine 10% underwent sutureless MMCR performed by the same surgeon. Pre- and postoperative margin-reflex distance 1 (MRD1) measurements were collected at baseline, and at 1 and 8 weeks after surgery. Data were collected from the files of 147 patients (252 eyes) with moderate to severe ptosis (MRD1, 0-2 mm) who underwent sutureless MMCR between October 2019 and October 2023.
RESULTS: Surgical success (defined as a postoperative MRD1 of ≥3 mm or ±0.5 mm of the preoperative MRD1 after phenylephrine instillation) was achieved in 88.5% of cases, with a mean [standard deviation] MRD1 improvement of 1.61 [0.89] mm (P < .001). Symmetry (defined as ≤1 mm difference in MRD1 between eyes) was obtained in 93.3% of bilateral cases. There was no significant difference between preoperative MRD1 after phenylephrine and postoperative MRD1 at 8 weeks (P = .54). Female patients had higher surgical success rates (odds ratio, 2.22; 95% CI, 1.01-4.95, P = .047). Complications were minimal, with wound dehiscence occurring in 1.19% of cases. Statistical analysis, including univariable and multivariable regression, was performed to assess factors associated with surgical outcomes.
CONCLUSIONS: Sutureless MMCR demonstrated high success rates and postoperative symmetry, with low complication rates, supporting its efficacy as a reliable and minimally invasive procedure for the treatment of ptosis.
OBJECTIVES: The aim of this study was to evaluate the efficacy and safety of sutureless MMCR as a treatment for moderate to severe ptosis, and to assess postoperative eyelid symmetry and surgical success rates.
METHODS: A retrospective, single-center cohort study was performed. Patients with a positive response to phenylephrine 10% underwent sutureless MMCR performed by the same surgeon. Pre- and postoperative margin-reflex distance 1 (MRD1) measurements were collected at baseline, and at 1 and 8 weeks after surgery. Data were collected from the files of 147 patients (252 eyes) with moderate to severe ptosis (MRD1, 0-2 mm) who underwent sutureless MMCR between October 2019 and October 2023.
RESULTS: Surgical success (defined as a postoperative MRD1 of ≥3 mm or ±0.5 mm of the preoperative MRD1 after phenylephrine instillation) was achieved in 88.5% of cases, with a mean [standard deviation] MRD1 improvement of 1.61 [0.89] mm (P < .001). Symmetry (defined as ≤1 mm difference in MRD1 between eyes) was obtained in 93.3% of bilateral cases. There was no significant difference between preoperative MRD1 after phenylephrine and postoperative MRD1 at 8 weeks (P = .54). Female patients had higher surgical success rates (odds ratio, 2.22; 95% CI, 1.01-4.95, P = .047). Complications were minimal, with wound dehiscence occurring in 1.19% of cases. Statistical analysis, including univariable and multivariable regression, was performed to assess factors associated with surgical outcomes.
CONCLUSIONS: Sutureless MMCR demonstrated high success rates and postoperative symmetry, with low complication rates, supporting its efficacy as a reliable and minimally invasive procedure for the treatment of ptosis.